Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 1Phase 1/2 1

Status

Completed 5Active not recruiting 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5Thoracic 1Gynecologic 1Genitourinary 1CNS 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 26Parkinson Disease 4, Autosomal Dominant Lewy Body 21Breast Neoplasms 17Neoplasms 16Multiple Myeloma 16Leukemia, Myeloid, Acute 15Recurrence 10Colorectal Neoplasms 10Myelodysplastic Syndromes 9Lymphoma, Non-Hodgkin 8Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Leukemia 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Melanoma 7Lymphoma, Follicular 7Carcinoma, Renal Cell 7Carcinoma, Hepatocellular 7Stomach Neoplasms 6Ovarian Neoplasms 6Lymphoma, Large B-Cell, Diffuse 6Leukemia, Lymphocytic, Chronic, B-Cell 6Uterine Cervical Neoplasms 5Purpura, Thrombocytopenic, Idiopathic 5Neoplasm Metastasis 5Lymphoma, Mantle-Cell 5Lung Neoplasms 5Graft vs Host Disease 5Esophageal Neoplasms 5Bronchiolitis Obliterans Syndrome 5Adenocarcinoma 5

Interventions

pembrolizumab 3Paclitaxel 2Docetaxel 2sacituzumab govitecan 1Nivolumab 1Irinotecan 1Fluorouracil 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × Has announcements × Esophageal Neoplasms × Clear all
NCT03189719 2024-10-15

KEYNOTE-590

Merck Sharp & Dohme LLC

Phase 3 Completed
749 enrolled 40 charts 1 FDA
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT02564263 2023-03-13

KEYNOTE-181

Merck Sharp & Dohme LLC

Phase 3 Completed
628 enrolled 27 charts 1 FDA
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT02559687 2022-09-14

KEYNOTE-180

Merck Sharp & Dohme LLC

Phase 2 Completed
121 enrolled 14 charts 1 FDA
Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT02569242 2022-07-06

Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer

Ono Pharmaceutical Co., Ltd.

Phase 3 Completed
419 enrolled 20 charts 1 FDA
Gastrointestinal

Esophageal Neoplasms

NCT01631552 2021-08-12

Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer

Gilead Sciences

Phase 1/2 Completed
515 enrolled 28 charts 1 FDA
BreastCNSGastrointestinalGenitourinaryGynecologicThoracic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡